Philip A. Hipskind

3.1k citations

41 papers · 2.2k indexed · h-index 23

Molecular Biology top 10%
Organic Chemistry top 5%
Cellular and Molecular Neuroscience top 5%
Infectious Diseases top 5%
Behavioral Neuroscience top 2%

Co-authors: Donald R. Gehlert Magnus Berglund Markus Heilig Michal Vieth Christina S. Barr Roberto Rimondini Wolfgang H. Sommer Anita C. Hansson
Topics: Neuropeptides and Animal Physiology (12 papers)Receptor Mechanisms and Signaling (12 papers)Tuberculosis Research and Epidemiology (11 papers)
Cited by: Behavioral Neuroscience Biological Psychiatry Cellular and Molecular Neuroscience
Journals: Journal of Neuroscience PLoS ONE Biochemistry
Partner nations: United States India Italy

In The Last Decade

Philip A. Hipskind

41 papers receiving 2.1k citations

Peers

Countries citing papers authored by Philip A. Hipskind

Since Specialization

Citations

This map shows the geographic impact of Philip A. Hipskind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip A. Hipskind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip A. Hipskind more than expected).

Fields of papers citing papers by Philip A. Hipskind

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip A. Hipskind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip A. Hipskind. The network helps show where Philip A. Hipskind may publish in the future.

Co-authorship network of co-authors of Philip A. Hipskind

This figure shows the co-authorship network connecting the top 25 collaborators of Philip A. Hipskind. A scholar is included among the top collaborators of Philip A. Hipskind based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip A. Hipskind. Philip A. Hipskind is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia 2020 ·PLoS ONE ·(unknown),(unknown),Michal Vieth,Philip A. Hipskind,Kasturi Haldar,Antonella Pantaleo,Francesco Turrini,Philip S. Low	14
2	Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition 2019 ·Molecular Cancer Therapeutics ·Anthony S. Fischl,Xiaoen Wang,Beverly L. Falcón,(unknown),Diane Bodenmiller,Glenn F. Evans,Julie Stewart,(unknown),Philip A. Hipskind,Jason R. Manro,Mark Uhlik,Sudhakar Chintharlapalli,Damien Gerald,David C. Alsop,Laura E. Benjamin,Rupal S. Bhatt	16
3	Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis 2018 ·ACS Infectious Diseases ·Julie V. Early,Juliane Ollinger,Crystal M. Darby,Torey Alling,Steven F. Mullen,Allen Casey,Ben Gold,(unknown),(unknown),Thierry Masquelin,Carl Nathan,Philip A. Hipskind,Tanya Parish	25
4	The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents 2017 ·Bioorganic & Medicinal Chemistry ·Edison S. Zuniga,Aaron Korkegian,Steven F. Mullen,Erik J. Hembre,Paul L. Ornstein,Guillermo S. Cortez,Kallolmay Biswas,(unknown),Jeffrey W. Cramer,Thierry Masquelin,Philip A. Hipskind,Joshua Odingo,Tanya Parish	44
5	Synthesis and Evaluation of the 2-Aminothiazoles as Anti-Tubercular Agents 2016 ·PLoS ONE ·Edward A. Kesicki,Mai A. Bailey,Yulia Ovechkina,Julie V. Early,Torey Alling,(unknown),Edison S. Zuniga,(unknown),(unknown),Thierry Masquelin,Philip A. Hipskind,Joshua Odingo,Tanya Parish	50
6	Synthesis and evaluation of the 2,4-diaminoquinazoline series as anti-tubercular agents 2014 ·Bioorganic & Medicinal Chemistry ·Joshua Odingo,Theresa O’Malley,Edward A. Kesicki,Torey Alling,Mai A. Bailey,Julie V. Early,Juliane Ollinger,(unknown),(unknown),Ravindra Singh,Philip A. Hipskind,Jeffrey W. Cramer,Thomas R. Ioerger,James C. Sacchettini,Richard Vickers,Tanya Parish	26
7	Bioorganic & Medicinal Chemistry 22 (2014) 6965–6979 2014 ·(unknown),Theresa O’Malley,Edward A. Kesicki,Torey Alling,Mai A. Bailey,Julie V. Early,Juliane Ollinger,(unknown),(unknown),Ravindra Singh,Philip A. Hipskind,Jeffrey W. Cramer,Thomas R. Ioerger,James C. Sacchettini,Richard Vickers,(unknown)	24
8	A High-Throughput Screen against Pantothenate Synthetase (PanC) Identifies 3-Biphenyl-4-Cyanopyrrole-2-Carboxylic Acids as a New Class of Inhibitor with Activity against Mycobacterium tuberculosis 2013 ·PLoS ONE ·Anuradha Kumar,Allen Casey,Joshua Odingo,Edward A. Kesicki,Garth L. Abrahams,Michal Vieth,Thierry Masquelin,Valerie Mizrahi,Philip A. Hipskind,David R. Sherman,Tanya Parish	36
9	Lipoamide Channel-Binding Sulfonamides Selectively Inhibit Mycobacterial Lipoamide Dehydrogenase 2013 ·Biochemistry ·Ruslana Bryk,(unknown),(unknown),Anand Balakrishnan,Ying‐Ta Wu,Chi‐Huey Wong,Thierry Masquelin,Philip A. Hipskind,Christopher D. Lima,Carl Nathan	17
10	3-(4-Chloro-2-Morpholin-4-yl-Thiazol-5-yl)-8-(1-Ethylpropyl)-2,6-Dimethyl-Imidazo[1,2-b]Pyridazine: A Novel Brain-Penetrant, Orally Available Corticotropin-Releasing Factor Receptor 1 Antagonist with Efficacy in Animal Models of Alcoholism 2007 ·Journal of Neuroscience ·Donald R. Gehlert,Andrea Cippitelli,Annika Thorsell,Anh D. Lê,Philip A. Hipskind,Chafiq Hamdouchi,Jian‐Liang Lu,Erik J. Hembre,Jeffrey W. Cramer,Min Song,David L. McKinzie,Michelle Morin,Roberto Ciccocioppo,Markus Heilig	194
11	Upregulation of Voluntary Alcohol Intake, Behavioral Sensitivity to Stress, and Amygdala Crhr1 Expression Following a History of Dependence 2007 ·Biological Psychiatry ·Wolfgang H. Sommer,Roberto Rimondini,Anita C. Hansson,Philip A. Hipskind,Donald R. Gehlert,Christina S. Barr,Markus Heilig	260
12	Synthesis and SAR of novel histamine H3 receptor antagonists 2006 ·Bioorganic & Medicinal Chemistry Letters ·Cynthia D. Jesudason,Lisa S. Beavers,Jeffrey W. Cramer,(unknown),(unknown),Craig W. Lindsley,Frits C. Stevens,Robert A. Gadski,(unknown),Richard T. Pickard,(unknown),Dana K. Sindelar,Ajay Singh,Brian M. Watson,Philip A. Hipskind	32
13	Acyl sulfonamide anti-proliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives 2004 ·Bioorganic & Medicinal Chemistry Letters ·Mary M. Mader,Chuan Shih,Eileen L. Considine,Alfonso de Dios,(unknown),Philip A. Hipskind,Ho‐Shen Lin,Karen L. Lobb,(unknown),José Enrique López,L. M. MARTIN CABREJAS,(unknown),(unknown),Yiu‐Yin Cheung,(unknown),(unknown),Sean R. Dinn	33
14	Recent Developments in Our Understanding of the Physiological Role of PP-Fold Peptide Receptor Subtypes 2003 ·Experimental Biology and Medicine ·Magnus Berglund,Philip A. Hipskind,Donald R. Gehlert	190
15	Expedited discovery of second generation NK-1 antagonists: identification of a nonbasic aryloxy substituent 2001 ·Bioorganic & Medicinal Chemistry Letters ·James E. Fritz,Philip A. Hipskind,Karen L. Lobb,James A. Nixon,Penny G. Threlkeld,Bruce D. Gitter,Carl L. McMillian,Stephen W. Kaldor	11
16	Structure-activity relationship of a series of diaminoalkyl substituted benzimidazole as neuropeptide Y Y1 receptor antagonists 1999 ·Bioorganic & Medicinal Chemistry Letters ·Hamideh Zarrinmayeh,Dennis M. Zimmerman,Buddy E. Cantrell,Douglas A. Schober,(unknown),Susan L. Gackenheimer,Paul L. Ornstein,Philip A. Hipskind,Thomas C. Britton,Donald R. Gehlert	82
17	Structure-activity relationships of a series of 1-substituted-4-methylbenzimidazole neuropeptide Y-1 receptor antagonists 1998 ·Bioorganic & Medicinal Chemistry Letters ·Dennis M. Zimmerman,Buddy E. Cantrell,Edward C. Smith,James A. Nixon,Robert F. Bruns,Bruce D. Gitter,Philip A. Hipskind,Paul L. Ornstein,Hamideh Zarrinmayeh,Thomas C. Britton,Douglas A. Schober,Donald R. Gehlert	14
18	Neuropeptide Y receptor antagonists in obesity 1997 ·Expert Opinion on Investigational Drugs ·Donald R. Gehlert,Philip A. Hipskind	12
19	Peripheral effects of three novel non-peptide tachykinin NK1 receptor antagonists in the anaesthetized rat 1996 ·European Journal of Pharmacology ·(unknown),(unknown),Philip A. Hipskind,Smriti Iyengar,Réjean Couture	13
20	[³H]LY303870, a Novel Nonpeptide Radioligand for the NK‐1 Receptor 1996 ·Journal of Neurochemistry ·Donald R. Gehlert,Douglas A. Schober,Philip A. Hipskind,Bruce D. Gitter,J. Jeffry Howbert	6

About Philip A. Hipskind

Philip A. Hipskind is a scholar working on Toxicology, Cellular and Molecular Neuroscience and Infectious Diseases, having authored 41 papers that have together received 2.2k indexed citations. Recurring topics across this work include Neuropeptides and Animal Physiology (12 papers), Receptor Mechanisms and Signaling (12 papers) and Tuberculosis Research and Epidemiology (11 papers). The work is most often cited by research in Behavioral Neuroscience (241 citations), Biological Psychiatry (86 citations) and Cellular and Molecular Neuroscience (617 citations). Philip A. Hipskind has collaborated with scholars based in United States, India and Italy. Frequent co-authors include Donald R. Gehlert, Magnus Berglund, Markus Heilig, Michal Vieth, Christina S. Barr, Roberto Rimondini, Wolfgang H. Sommer, Anita C. Hansson, Marvin J. Miller and Garrett C. Moraski. Their work appears in journals such as Journal of Neuroscience, PLoS ONE and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact